A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
← catalyst calendarNCT05529316 · readout ≤ 559 d
Sponsored by Agenus Inc. (industry) · AGEN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
150actual
Sites
51
Countries
Belgium, Brazil, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-12 | actual | When the study began enrolling |
| Primary completion | Feb 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2022-09-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Melanoma
Interventions
- Drug: Botensilimab — also filed as AGEN1181
- Drug: Balstilimab — also filed as AGEN2034
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate
measured First dose through up to 3 months
Permalink · AGEN's whole pipeline · Catalyst calendar · Every registered study · What changed